ALCHEMIST Screening Trial
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST Screening Trial)
This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Sponsor: National Cancer Institute
Juile Ward, RN, BSN
For pre-surgical patients
◦Suspected diagnosis of resectable non-small cell lung cancer
◦Suspected clinical stage of IIIA, II or large IB (defined as size >= 4cm)
For post-surgical patients
◦Completely resected non-small cell lung cancer
◦Pathologic stage IIIA, II or IB (defined as size >= 4 cm)
For all patients
•No patients who have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer
•No prior or concurrent malignancies within 5 years, except non-melanoma skin carcinoma or in situ carcinomas; a secondary primary lung cancer is considered a concurrent malignancy and would make a patient ineligible.
•No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD-1/PD-L1/CTLA-4
For more information, https://clinicaltrials.gov/ct2/show/NCT02194738